CHEMOTHERAPY OF COLORECTAL-CANCER

被引:26
作者
BLIJHAM, GH
机构
关键词
CHEMOTHERAPY; COLORECTAL CANCER; 5-FU;
D O I
10.1097/00001813-199106000-00003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Advanced colorectal cancer belongs to the most chemotherapy-resistant human malignancies. The cytotoxic agent with the most consistent antitumor activity has been 5-fluorouracil (5-FU). With this drug, response rates vary between 15% (with conventional weekly or 5-day bolus injection) and 30% (with continuous infusions of 24 h to 12 weeks); survival advantages of the latter approach have not been demonstrated. Combinations of 5-FU with other cytotoxic agents with some activity have been found unsuccessful. Because of its complex metabolism the efficacy-toxicity ratio of 5-FU can be positively influenced by biochemical modulation with agents leading to decrecreased availability of competing substrates, increased availability of co-substrates or more efficient interactions with target substances. Superior response rates (20-40%) have been observed upon the addition of leucovorin methotrexate and N-(phosphonacetyl)-L-aspartic acid; survival was modestly prolonged (2-3 months) in two leucovorin and one methotrexate study. Interferon-alpha, inactive as a single agent, appears to synergize with 5-FU at the cost of considerable toxicity; results from randomized trials of this combination are awaited. 5-FU has also been the mainstay of adjuvant treatments; in poor-prognosis rectal cancer it appears to improve survival if added to radiotherapy, whereas in combination with levamisol the survival of node-positive colonic carcinoma patients can be prolonged.
引用
收藏
页码:233 / 245
页数:13
相关论文
共 135 条
[1]  
AHLGREN JD, 1990, P ASCO, V9, P119
[2]  
[Anonymous], 1985, NEW ENGL J MED, V312, P1465
[3]  
ANSFIELD F, 1977, CANCER-AM CANCER SOC, V39, P34, DOI 10.1002/1097-0142(197701)39:1<34::AID-CNCR2820390107>3.0.CO
[4]  
2-2
[5]  
ARDALAN B, 1984, CANCER TREAT REP, V68, P531
[6]   AN UPDATE ON THE BIOCHEMISTRY OF 5-FLUOROURACIL [J].
ARDALAN, B ;
GLAZER, R .
CANCER TREATMENT REVIEWS, 1981, 8 (03) :157-167
[7]   SYNERGISTIC EFFECT OF 5-FLUOROURACIL AND N-(PHOSPHONACETYL)-L-ASPARTATE ON CELL-GROWTH AND RIBONUCLEIC-ACID SYNTHESIS IN A HUMAN MAMMARY-CARCINOMA [J].
ARDALAN, B ;
GLAZER, RI ;
KENSLER, TW ;
JAYARAM, HN ;
VANPHAM, T ;
MACDONALD, JS ;
COONEY, DA .
BIOCHEMICAL PHARMACOLOGY, 1981, 30 (15) :2045-2049
[8]   A RANDOMIZED PHASE-I AND PHASE-II STUDY OF SHORT-TERM INFUSION OF HIGH-DOSE FLUOROURACIL WITH OR WITHOUT N-(PHOSPHONACETYL)-L-ASPARTIC ACID IN PATIENTS WITH ADVANCED PANCREATIC AND COLORECTAL CANCERS [J].
ARDALAN, B ;
SINGH, G ;
SILBERMAN, H .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (06) :1053-1058
[9]  
ARNAUD JP, 1989, P EORTC S ADV GASTRA, P128
[10]   HOME THERAPY WITH RECOMBINANT INTERLEUKIN-2 AND INTERFERON-ALPHA-2B IN ADVANCED HUMAN MALIGNANCIES [J].
ATZPODIEN, J ;
KORFER, A ;
FRANKS, CR ;
POLIWODA, H ;
KIRCHNER, H .
LANCET, 1990, 335 (8704) :1509-1512